Basel Medical Group Ltd
BMGL
$4.18
$0.01140.27%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | 5.29% | 5.82% | 3.75% | 4.57% | |
| Total Other Revenue | -58.75% | -58.39% | -25.00% | -25.00% | |
| Total Revenue | 4.71% | 5.23% | 3.75% | 4.56% | |
| Cost of Revenue | 54.34% | 55.13% | -23.28% | -22.67% | |
| Gross Profit | -35.68% | -35.35% | 63.60% | 64.91% | |
| SG&A Expenses | -33.28% | -32.96% | -81.54% | -81.25% | |
| Depreciation & Amortization | 10.56% | 11.07% | -15.19% | -14.52% | |
| Other Operating Expenses | 2,195.95% | 2,186.67% | -31.24% | -30.69% | |
| Total Operating Expenses | 37.10% | 37.79% | -23.90% | -23.29% | |
| Operating Income | -79.88% | -79.79% | 175.24% | 177.44% | |
| Income Before Tax | -69.90% | -69.75% | 232.96% | 235.45% | |
| Income Tax Expenses | -178.20% | -178.54% | 11,430.00% | 11,430.00% | |
| Earnings from Continuing Operations | -37.40% | -37.07% | 125.71% | 127.49% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -37.40% | -37.07% | 125.71% | 127.49% | |
| EBIT | -79.88% | -79.79% | 175.24% | 177.44% | |
| EBITDA | -79.05% | -78.92% | 171.72% | 173.85% | |
| EPS Basic | -37.27% | -37.13% | 126.12% | 127.82% | |
| Normalized Basic EPS | -70.00% | -69.68% | 232.53% | 236.59% | |
| EPS Diluted | -37.27% | -37.13% | 126.12% | 127.82% | |
| Normalized Diluted EPS | -70.00% | -69.68% | 232.53% | 236.59% | |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |